Trump Says All 50 States, D.C. and Puerto Rico Have Joined Medicaid 'Most Favored Nation' Drug Pricing Model
The White House says the GENEROUS model will cut Medicaid prices on selected brand-name drugs to levels paid abroad; the separate ACA cost-sharing proposal Trump referenced dates to his January 2026 plan and still needs Congress.
A Drug Price Deal Every Governor Signed and Almost No One Can Verify
Fifty states. Washington, D.C. Puerto Rico. Every one of them has now signed on to a new Medicaid drug pricing program, President Trump announced from the White House on Friday, September 18, 2026[1][3]. That is the headline fact, and it isn't in dispute. What's in dispute is what the sign-up actually proves.
The program is called the GENEROUS model. Under it, drugmakers give state Medicaid programs extra rebates on a set of expensive brand-name drugs[1]. The goal is to push what Medicaid actually pays down toward the "most favored nation" price — roughly the lowest price the same drug sells for in other wealthy countries[1][2]. The idea: if a company sells a drug for less in France or Japan, Medicaid should get close to that price too.
Here's the thing nobody disputes and nobody can check at the same time. The White House's own Council of Economic Advisers estimates the deal will save the federal government $36.6 billion and state governments $27.6 billion over ten years — about $64 billion combined[1][4]. But the actual contracts with drugmakers, the ones that would let an outsider check that math, are confidential[3][4][7]. Every wire report on the announcement carried that caveat. Whether it landed high in the story or buried near the bottom depended a lot on which outlet you read.
Why the Same Discount Buys Less Here Than It Would Elsewhere
To understand why some health policy analysts are cautious about the size of these savings, you need to know one fact about Medicaid that doesn't apply to other U.S. health programs: it already gets the best price in the country[5][6]. Federal law forces drugmakers to give Medicaid large mandatory rebates no other buyer receives. So GENEROUS isn't applying a discount to a drug's sticker price — it's trying to squeeze a further discount out of a price that's already been discounted once[5][6].
That's the structural reason analysts at KFF and in a New England Journal of Medicine perspective piece expect smaller gains from this program than a similar most-favored-nation plan would produce in Medicare, where prices start much higher[5][6]. It doesn't mean the savings are fake. It means the room to save more is narrower here than the topline numbers might suggest to a reader seeing them for the first time.
There's also a mechanical reason to expect a limited direct effect on individual Medicaid patients. Roughly 70 million people are covered by Medicaid, and their drug costs are split between federal and state governments[2]. A rebate lowers what those governments pay. It doesn't directly lower what a Medicaid patient pays at the pharmacy counter, because Medicaid copays are already close to nothing. The people facing the sharpest cost increases in 2026 aren't on Medicaid at all — they're enrolled in Affordable Care Act exchange plans, a separate and much more painful story that Trump also raised at the same event.
What Drugmakers Got for Saying Yes
More than two dozen manufacturers — 26 of them, covering close to 90% of the branded U.S. drug market — have signed most-favored-nation agreements with the administration since 2025[1][3][4]. That participation is technically voluntary. No law requires a company to sign.
But several of those manufacturers received tariff relief and exemptions from a tougher most-favored-nation pricing model aimed at Medicare, in connection with agreeing to the Medicaid terms[6][8]. In plain terms: sign a manageable concession in the smaller, lower-margin Medicaid program, and get protection from a much costlier version of the same policy elsewhere. Axios and The Hill both framed the announcement around this trade rather than treating it as a simple price cut[7][8][9].
PhRMA, the industry's main lobbying group, still opposes the broader approach. Its CEO, Steve Ubl, called it "importing foreign prices from socialist countries[3]." That's a genuine industry position, not just spin — the argument is that U.S. prices fund the research that produces new drugs, and that importing foreign price levels risks importing the rationing that sometimes comes with them. It sits in real tension with the fact that individual companies are signing anyway, because for them the Medicaid trade is the better of two available deals.
The Confidentiality Both Sides Are Quiet About
Nobody involved is pushing hard to make these contracts public, and that's worth sitting with. Secret prices protect drugmakers from other buyers — private insurers, other governments — demanding the same terms they gave Medicaid[3][7]. Secret prices also let the administration publish a savings estimate that nobody outside government can audit[1][7].
Both sides benefit from the same opacity. That's different from either side hiding something scandalous. It's a shared incentive structure, and it explains why the loudest complaint from critics isn't "the deal is bad" — it's "we can't tell if the deal is good[7]." Fortune's headline on the story led with a source saying flatly, "No one knows what is in these deals[7]."
Senate Finance Committee ranking member Ron Wyden has been blunter about the administration's broader drug-pricing record, saying earlier this year, "There is no greater fraud than Donald J. Trump when it comes to lower drug prices," and pointing to list-price increases on hundreds of brand-name drugs in 2026[16]. The administration disputes that framing and points to the sign-up numbers as proof the deal works for state budgets across party lines — Republican governors Sarah Huckabee Sanders of Arkansas, Larry Rhoden of South Dakota, and Tate Reeves of Mississippi joined Trump on stage, alongside HHS Secretary Robert F. Kennedy Jr. and CMS Administrator Mehmet Oz[2].
The Other Health Care Story That Got Folded Into This One
Trump also renewed his call for Congress to fund Affordable Care Act cost-sharing reductions and to send subsidy money directly to consumers[12][13][18]. It's worth being precise about timing here, because coverage sometimes blurred it: this isn't a new September proposal. Trump first laid it out on January 15, 2026, as part of what the White House called "The Great Healthcare Plan[12][13][18]." It still needs Congress to act, and Congress hasn't[13][18].
The backdrop makes this piece of the announcement land harder than it otherwise would. Enhanced ACA premium tax credits expired December 31, 2025. Average 2026 exchange premiums roughly doubled afterward[15][17]. The Congressional Budget Office estimated that funding cost-sharing reductions could save taxpayers at least $36 billion and cut premiums on the most common plan type by more than 10%[14][15]. But CBO's own analysis also found a catch: because of an accounting quirk called "silver loading," where insurers currently price in the missing federal payments by raising silver-tier premiums (which also raises the subsidies tied to those premiums), fixing the underlying gap could shrink subsidies for other enrollees even as headline prices fall[14]. Some people could end up paying more, not less, depending on which plan and subsidy tier they're in.
What's Actually Settled, and What Isn't
Strip away the framing on both sides and a short list survives untouched. All 50 states, D.C., and Puerto Rico did sign up for GENEROUS[2][4]. The federal savings estimate is $36.6 billion and the state estimate is $27.6 billion over ten years, both from the administration's own economists[1][4]. The contracts behind those numbers are not public[3][4][7]. And the ACA cost-sharing fix Trump mentioned alongside the drug announcement is eight months old and still sitting in Congress, not a new policy[12][13][18].
What's still open is whether the size of the win matches the size of the announcement, and whether a Medicaid program already getting the country's steepest legal discount has much further to fall. The administration is treating the sign-up itself as the proof. Critics are treating the secrecy as the reason to withhold judgment. Both of those positions can be true about the same $64 billion estimate, and for now, neither one can be checked against the actual contracts that would settle it.
Summary
On Friday, September 18, 2026, President Donald Trump announced at the White House that all 50 states, Washington, D.C., and Puerto Rico have signed up for a Medicaid drug pricing program called the GENEROUS model[1][3]. Under it, drugmakers give state Medicaid programs extra rebates on selected expensive brand-name drugs. The goal is to push the final price Medicaid pays down to the "most favored nation" price — roughly the lowest price the same drug sells for in other rich countries[1][2]. Health and Human Services Secretary Robert F. Kennedy Jr., CMS Administrator Mehmet Oz, and three Republican governors appeared with him[2].
The White House Council of Economic Advisers estimates the Medicaid deals will save the federal government $36.6 billion and the states $27.6 billion over ten years — together about $64 billion[1][4]. The White House says 26 drugmakers, covering about 90% of the branded U.S. drug market, are taking part across its broader most-favored-nation push[1]. The administration calls the program a historic price cut for the roughly 70 million people on Medicaid[2].
The main dispute is not whether the states signed up. It is whether the savings are real and who paid for them. Reporters and health policy analysts point out that the contracts with drugmakers are confidential, so no one outside government can check the math[3][4][7]. Analysts at KFF and in a New England Journal of Medicine perspective note that Medicaid already receives the deepest legally required drug discounts in the country, which limits how much more an extra rebate can squeeze out[5][6]. Critics also note the manufacturers did not volunteer for free: several received tariff relief and exemptions from a tougher most-favored-nation plan for Medicare in exchange[7][8]. The drug industry's main lobby, PhRMA, opposes the approach from the other direction, calling it importing price controls from abroad[3].
One framing point needs a correction up front. The cost-sharing idea for Affordable Care Act exchange plans is not a new September proposal. Trump laid it out on January 15, 2026, as part of "The Great Healthcare Plan," and it still requires Congress to act[12][13][18]. That plan would have the government resume paying insurers for "cost-sharing reductions," and separately send money directly to consumers instead of to insurers[13][20]. The White House, citing Congressional Budget Office estimates, says funding cost-sharing reductions would save taxpayers at least $36 billion and cut ACA premiums by more than 10%[14][15].
The Event
On Friday, September 18, 2026, President Donald Trump announced from the White House that all 50 states, the District of Columbia, and Puerto Rico have applied to join the Medicaid GENEROUS payment model, which sets most-favored-nation prices for selected brand-name drugs in state Medicaid programs[1][3][9]. He was joined by HHS Secretary Robert F. Kennedy Jr., CMS Administrator Mehmet Oz, CMS Deputy Administrator Abe Sutton, and Governors Sarah Huckabee Sanders of Arkansas, Larry Rhoden of South Dakota, and Tate Reeves of Mississippi[2]. The White House Council of Economic Advisers put the ten-year savings at $36.6 billion for the federal government and $27.6 billion for states[1][4]. Trump also repeated his call for Congress to fund Affordable Care Act cost-sharing reductions and to send health subsidy money directly to consumers, proposals he first announced on January 15, 2026[12][13][18].
Undisputed Facts
- The announcement was made at the White House on Friday, September 18, 2026[1][3].
- All 50 states, Washington, D.C., and Puerto Rico have signed up for the Medicaid GENEROUS model[2][4].
- The White House Council of Economic Advisers estimates $36.6 billion in federal savings and $27.6 billion in state savings over ten years[1][4].
- More than two dozen drug manufacturers have signed most-favored-nation agreements with the administration since 2025, including Pfizer, Eli Lilly, and Novo Nordisk[3][4].
- Manufacturer participation in GENEROUS is voluntary, and several manufacturers received tariff relief and exemptions from a Medicare most-favored-nation model in connection with participating[6][8].
- The specific pricing terms in the manufacturer agreements have not been made public[3][4][7].
- The United States pays more for prescription drugs than any other country, often close to three times what other developed nations pay[4].
- Enhanced ACA premium tax credits expired on December 31, 2025, and average 2026 exchange premiums roughly doubled afterward[15][17].
- The ACA cost-sharing reduction funding proposal was announced January 15, 2026, as part of 'The Great Healthcare Plan' and requires action by Congress[12][13][18].
The Pressure
Strip away the moralizing and blame. What structural realities persist regardless of which narrative wins?
- Election-year cost politics
- Average ACA exchange premiums roughly doubled for 2026 after enhanced tax credits lapsed on December 31, 2025[15][17]. Health costs are therefore a live liability for the party in power, and a drug-price announcement is the fastest available counter-message[9].
- Medicaid is already the cheapest buyer
- Federal law already forces manufacturers to give Medicaid large mandatory rebates, deeper than any other U.S. purchaser gets[5][6]. That is the structural reason analysts expect smaller gains here than a Medicare version would produce — the discount is stacked on top of an existing discount, not applied to the sticker price.
- Leverage, not persuasion
- Participation is formally voluntary. But manufacturers have reported receiving tariff exemptions and relief from a Medicare most-favored-nation model in connection with signing[6][8]. The administration's real instrument is a threat elsewhere in its portfolio, not a Medicaid rule.
- Confidentiality protects both signatories
- Secret net prices let manufacturers avoid other buyers demanding the same terms, and let the government publish savings numbers nobody can audit[3][7]. Both parties benefit from the same opacity, which is why neither is pushing to end it.
Material realityRoughly 70 million people are covered by Medicaid, and their drug costs are split between federal and state budgets[2]. Any rebate lowers what governments pay; it does not directly lower what a Medicaid enrollee pays at the counter, because Medicaid copays are already nominal. The people facing the largest 2026 cost increases are not on Medicaid at all — they are ACA exchange enrollees whose enhanced tax credits expired at the end of 2025[15][17]. The Medicaid action is executive and already in motion; the ACA cost-sharing fix is a legislative proposal from January 2026 that Congress has not enacted[13][18]. Meanwhile, U.S. drug prices remain roughly three times those in peer countries, a gap this model narrows only for selected brand drugs in one program[4].
Narrative as a weaponThe White House is the most active shaper here: it supplied the sign-up count, the savings estimates, the participant list, and the framing that other countries have been free-riding on American patients[1][2]. It wants you to read a 52-jurisdiction sign-up as independent validation. Critics and much of the business press want you to read the same event as a trade — modest Medicaid concessions bought with tariff relief and Medicare protection — and to keep your attention on the doubled ACA premiums instead[7][8]. PhRMA wants you to believe the real risk is to future medicines, not to this year's budget[3]. The most useful thing a reader can hold onto is what nobody disputes: the contracts are secret, so every savings figure in this story, from any side, is currently an estimate rather than a measurement[3][4][7].
How Each Side Sees It
Each major actor’s view — how it frames things, its underlying incentive, and how it’s materially affected. Tap a side to read it.
Frames it asTheir core argument is fairness between countries. Americans invent and fund most new drugs, then pay the highest prices in the world for them, while other rich countries use their national health systems to force the price down[4]. Most-favored-nation pricing simply says: whatever the lowest price you give a wealthy country is, give it to us too[1]. The administration also argues the 50-state sign-up is its own proof of value — Democratic and Republican governors alike concluded the deal was good for their budgets, which is rare in health policy[2][9]. On the ACA side, the argument is that subsidy money currently flows to insurers and pharmacy middlemen, and should instead go to the patient, who can then shop[13][20]. Funding cost-sharing reductions, they argue, is not a bailout but a way to end an accounting workaround that inflates premiums[14].
WhyDeliver a visible cost-cutting win on health care before the 2026 midterms, at a moment when ACA premiums have roughly doubled and health costs poll badly for the party in power[15][17].
Impact on themThe administration controls the estimates, the timing, and the confidentiality of the deals, so it captures the political benefit immediately while the verifiable savings arrive years later[1][7].
Frames it asThe industry's strongest case is about where new medicines come from. High U.S. prices, they argue, fund the research that produces drugs the rest of the world then buys cheaply; importing foreign prices imports foreign rationing too[3]. PhRMA CEO Steve Ubl called the approach 'importing foreign prices from socialist countries'[3]. Individual companies took a narrower, pragmatic position: signing gets them tariff relief and an exemption from a harsher most-favored-nation model in Medicare, so a manageable Medicaid concession beats an unmanageable Medicare one[6][8]. They also note Medicaid is a small slice of their revenue relative to commercial insurance, which limits the real cost.
WhyTrade a limited, controllable price cut in the lowest-margin government program for protection from tariffs and from a far more costly Medicare policy[6][8].
Impact on themLower net prices on selected brand drugs in Medicaid, offset by tariff exemptions and reduced Medicare exposure; the confidentiality of the deals also shields them from other purchasers demanding the same terms[7].
Frames it asTheir central claim is a comparison, not a denial. Even if the Medicaid savings are real, they argue, they are small next to the premium increases Americans are already paying after enhanced ACA tax credits expired at the end of 2025[15][17]. Senate Finance ranking member Ron Wyden has said of Trump's drug pricing record, 'There is no greater fraud than Donald J. Trump when it comes to lower drug prices,' pointing to list-price increases on hundreds of brand-name drugs in 2026[16]. On the mechanics, they argue a deal the public cannot read is a deal the public cannot hold anyone to[7]. They also object that replacing ACA premium tax credits with direct payments shifts risk onto individuals, who would shop for coverage with a fixed sum instead of a subsidy that scales with the cost of a plan[13][20]. On cost-sharing reductions specifically, they note the Congressional Budget Office's own analysis found that while funding CSRs would cut the most common (silver) plan premiums by more than 10%, it would also reduce the subsidies many other exchange enrollees currently receive because of 'silver loading,' meaning some people would end up paying more even as headline premiums fall[14].
WhyKeep health costs at the center of the 2026 midterms and prevent the drug announcement from displacing the premium story[15].
Impact on themThey lose the ability to argue the administration has done nothing on drug prices, but gain a transparency line of attack that the confidential contracts do not answer[7].
Frames it asFor governors, the case is budgetary and close to risk-free. States share Medicaid costs with the federal government, so any rebate that lands flows partly into the state budget[1]. Signing up costs nothing upfront, and the model is voluntary for manufacturers rather than a state mandate. Republican governors who appeared with Trump — Sanders, Rhoden, and Reeves — presented it as fiscal relief for programs squeezed by drug spending[2]. Even states hostile to the administration on other health issues had little reason to refuse a discount.
WhyRelieve pressure on Medicaid drug budgets without spending political capital or state funds[1][2].
Impact on themProjected $27.6 billion in state savings over ten years per the Council of Economic Advisers — real money, but spread across 52 jurisdictions and ten years, and dependent on deal terms states themselves may not fully see[1][4][7].
Like this article?
The Bias Ledger average rating 4.4
The same story, as framed by outlets across the spectrum, ordered least to most biased. The bias score (1 = straight, 10 = heavily spun) is an AI assessment of that framing — click an outlet to see its track record. The tell is the word choice or omission that reveals the angle.
| Outlet | Vantage | Bias | How they frame it | The tell |
|---|---|---|---|---|
| Associated Press | U.S. center | 2 | 'Trump announces all 50 states joining Medicaid drug pricing model' — reports the claim, the CEA savings estimates, and the PhRMA objection in the same piece. | Includes the load-bearing caveat that savings are unverifiable because deal contents are not public, but places it below the administration's figures, so the numbers land first. |
| Reuters | U.S./U.K. center, wire | 2 | 'All 50 states sign up for Trump's Medicaid most-favored-nation plan' — procedural framing focused on the sign-up count. | Adds the comparative anchor that U.S. drug prices run near three times other developed nations', which makes the policy look more justified without endorsing the savings estimate. |
| The Hill | U.S. center | 2 | 'President Trump says all 50 states applied for new Medicaid drug pricing agreement' — attributes the claim to Trump in the headline itself. | The 'Trump says' construction is the most cautious framing in the set; it signals the sign-up figure comes from the administration, not independent confirmation. |
| Axios | U.S. center-left | 4 | 'Trump announces cheaper drugs for state Medicaid programs' — neutral headline, but the body foregrounds what drugmakers received in return. | Emphasis on the tariff relief and Medicare exemptions recasts a price cut as a negotiated trade, which shifts the reader toward skepticism before any savings figure appears. |
| Fortune | U.S. center-left business | 6 | 'No one knows what is in these deals': Trump set to announce new Medicaid drug pricing model amid affordability concerns. | Leads with a critic's quotation as the headline and pairs the announcement with 'affordability concerns' — linking the drug news to the separate ACA premium story before the article argues the connection. |
| Breitbart | U.S. right | 7 | 'Trump: Most-Favored-Nation Drug Pricing Being Extended to State Medicaid Programs' — presented as a delivered promise. | Omits the confidentiality caveat and the tariff-relief trade entirely, so the savings estimate reads as a measured outcome rather than a projection by the administration's own economists. |
| RedState | U.S. right, opinion-driven | 8 | 'Trump Has More Great News About Savings From Most Favored Nation Drug Prices' — celebratory framing in the headline. | 'Great news' is the outlet's own characterization, not an attributed one, and no critic or analyst appears to test the figures. |
References
- Fact Sheet: President Donald J. Trump Announces Lower Drug Prices for All 50 State Medicaid Programs — The White House · U.S. executive branch; the announcing party and author of the savings estimates
- President Trump Extends Most Favored Nation Drug Pricing to Every Medicaid Program in America — The White House · U.S. executive branch communications
- Trump announces all 50 states joining Medicaid drug pricing model — Associated Press · U.S. nonprofit wire cooperative; centrist news conventions
- All 50 States Sign up for Trump's Medicaid Most-Favored-Nation Plan — Reuters · U.K.-headquartered commercial wire; business-oriented centrist
- A Look at the GENEROUS Model and Factors That Could Impact Medicaid Drug Costs — KFF · U.S. health policy research organization, endowment-funded; widely cited across the spectrum but its analysts generally favor coverage expansion
- Medicaid's GENEROUS Most-Favored-Nation Pricing Model — Promise and Limitations — New England Journal of Medicine · Peer-reviewed medical journal; Perspective pieces are signed academic opinion, not journal position
- 'No one knows what is in these deals': Trump set to announce new Medicaid drug pricing model amid affordability concerns — Fortune · U.S. business magazine; center-left editorial tilt in political coverage
- Trump announces cheaper drugs for state Medicaid programs — Axios · U.S. digital outlet; center-left, heavy insider-sourcing
- President Trump says all 50 states applied for new Medicaid drug pricing agreement — The Hill · U.S. Capitol Hill trade publication; centrist newsroom, ideologically mixed opinion section
- Trump: Most-Favored-Nation Drug Pricing Being Extended to State Medicaid Programs — Breitbart · U.S. right, explicitly pro-Trump
- Trump Has More Great News About Savings From 'Most Favored Nation' Drug Prices — RedState · U.S. right, opinion blog network
- Trump pitches direct payments to consumers for health care. What policy experts say about the plan — CNBC · U.S. business news; market-focused, centrist
- Trump announces health care plan to cut ACA costs requiring Congress' approval — NBC News · U.S. broadcast network news; center-left
- White House Releases 'Great Healthcare Plan' — Committee for a Responsible Federal Budget · U.S. deficit-reduction advocacy group, corporate- and foundation-funded; fiscally hawkish, not neutral
- Trump unveils healthcare affordability plan — Healthcare Dive · U.S. industry trade publication for health care executives
- Wyden, Senate Democrats Blast Trump's Drug Pricing Fraud, Lay Out Agenda for Lower Prices — U.S. Senate Committee on Finance, Democratic staff · Democratic Party congressional communications; partisan by design
- Health subsidies expire, launching millions of Americans into 2026 with steep insurance hikes — PBS NewsHour · U.S. public broadcaster; center to center-left
- President Trump Unveils The Great Healthcare Plan to Lower Costs and Deliver Money Directly to the People — The White House · U.S. executive branch communications
- President Trump Makes an Announcement on Healthcare, Sep. 18, 2026 (video) — The White House · U.S. executive branch primary record
- Trump Announces 'The Great Healthcare Plan,' Proposing Direct Payments, Price Transparency, Insurance Reform — The American Journal of Managed Care · U.S. managed-care trade journal; industry readership